Henry F. VanBrocklin, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Henry F. VanBrocklin, PhD

Professor, Department of Radiology, and Director of Radiopharmaceutical Research, UCSF

HFVanBrocklin@lbl.gov

Phone: (510) 486-4083 (voice)
Lawrence Berkeley Nat'l Laboratory, 1 Cyclotron Road, MS 55-121, Berkeley, CA 94720

UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics

Research Summary

I have over 25 years’ experience with the preparation and application of radiopharmaceuticals. I have developed several imaging agents targeting cell surface proteins (receptors, enzymes and transporters) including receptor-based imaging agents for hormone receptors, growth factor receptors, neuroreceptors, and prostate-specific membrane antigen. I have developed imaging agents for cardiac blood flow and metabolism. These imaging agents have included a broad range of molecular motifs from small molecules, antibodies, antibody fragments (e.g., Fabs, scFv, and diabodies), and aptamers, to proteins and peptides. These molecules have been labeled with a variety of isotopes for PET and SPECT imaging. As part of the development of these imaging agents, I have been engaged in the evaluation and validation of the tracer mechanism of localization and retention at the target site. I have prepared several in vitro and in vivo model systems and interpreted the data collected from these systems to determine the utility of the probes. I have successfully translated many of these tracers into humans. I have helped to write and secure several INDs for first-in-human tracer studies.
Over the last 10 years, I have been working on the development of PSMA targeting prostate cancer imaging agents in collaboration with Dr. Clifford Berkman at Washington State University. I am currently PI on a DoD PCRP-funded proposal to prepare these agents for human imaging studies. I am also UCSF PI on an NIH SBIR funded to perform the first-in-man PET/MRI imaging studies. I am currently also evaluating a new agent to measure T cell activation, 18F-FAraG. The pharmacokinetics of agent has been assessed in normal human subjects and will be further evaluated following immunotherapy response.

Education

Rensselaer Polytechnic Institute, Troy, NY, B.S., 1984, Chemistry
Rensselaer Polytechnic Institute, Troy, NY, M.S., 1986, Nuclear Chemistry
Washington University, St. Louis, MO, M.A., 1988, Nuclear Chemistry
Washington University, St. Louis, MO, Ph.D., 1990, Radiopharm. Chemistry
University of Illinois, Urbana, IL, Postdoctoral, 1992, Radiopharm. Chemistry


Professional Experience

  • 1990-1992
    DOE Alexander Hollaender Distinguished Postdoctoral Fellow, University of Illinois
  • 1992-present
    Chief Chemist, Head, Radiochemistry, Center for Functional Imaging, Lawrence Berkeley National Laboratory
  • 1992-2005
    Assistant Adjunct Professor of Radiology, University of California San Francisco
  • 2005-present
    Professor of Radiology, University of California San Francisco
  • 2005-present
    Joint Faculty Scientist, Department of Functional Imaging, LBNL

Honors & Awards

  • 1990-1992
    DOE Alexander Hollaender Distinguished Postdoctoral Fellowship
    Lawrence Berkeley National Laboratory Outstanding Performance Award (1993, 1997, 1998, 2000)
  • 2006
    SNM President's Distinguished Service Award

Selected Publications

  1. Dannoon S, Ganguly T, Cahaya H, Geruntho JJ, Galliher MS, Beyer SK, Choy CJ, Hopkins MR, Regan M, Blecha JE, Skultetyova L, Drake CR, Jivan S, Barinka C, Jones EF, Berkman CE, VanBrocklin HF. Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. J Med Chem. 2016 Jun 23; 59(12):5684-94.
    View on PubMed
  2. Li L, Che L, Wang C, Blecha JE, Li X, VanBrocklin HF, Calvisi DF, Puchowicz M, Chen X, Seo Y. [(11)C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice. Mol Imaging Biol. 2016 Jun; 18(3):360-7.
    View on PubMed
  3. Schankin CJ, Maniyar FH, Seo Y, Kori S, Eller M, Chou DE, Blecha J, Murphy ST, Hawkins RA, Sprenger T, VanBrocklin HF, Goadsby PJ. Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. Brain. 2016 Jul; 139(Pt 7):1994-2001.
    View on PubMed
  4. Drake CR, Sevillano N, Truillet C, Craik CS, VanBrocklin HF, Evans MJ. Site-Specific Radiofluorination of Biomolecules with 8-[(18)F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase. ACS Chem Biol. 2016 Jun 17; 11(6):1587-94.
    View on PubMed
  5. Carroll VN, Truillet C, Shen B, Flavell RR, Shao X, Evans MJ, VanBrocklin HF, Scott PJ, Chin FT, Wilson DM. [(11)C]Ascorbic and [(11)C]dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography. Chem Commun (Camb). 2016 Apr 7; 52(27):4888-90.
    View on PubMed
  6. Korenchan DE, Flavell RR, Baligand C, Sriram R, Neumann K, Sukumar S, VanBrocklin H, Vigneron DB, Wilson DM, Kurhanewicz J. Dynamic nuclear polarization of biocompatible (13)C-enriched carbonates for in vivo pH imaging. Chem Commun (Camb). 2016 Feb 9; 52(14):3030-3.
    View on PubMed
  7. Flavell RR, Truillet C, Regan MK, Ganguly T, Blecha JE, Kurhanewicz J, VanBrocklin HF, Keshari KR, Chang CJ, Evans MJ, Wilson DM. Caged [(18)F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography. Bioconjug Chem. 2016 Jan 20; 27(1):170-8.
    View on PubMed
  8. Page MJ, Lourenço AL, David T, LeBeau AM, Cattaruzza F, Castro HC, VanBrocklin HF, Coughlin SR, Craik CS. Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography. Nat Commun. 2015; 6:8448.
    View on PubMed
  9. Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015 Aug; 40(6):1432-40.
    View on PubMed
  10. Keshari KR, Wilson DM, Van Criekinge M, Sriram R, Koelsch BL, Wang ZJ, VanBrocklin HF, Peehl DM, O'Brien T, Sampath D, Carano RA, Kurhanewicz J. Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor. Prostate. 2015 Oct; 75(14):1601-9.
    View on PubMed
  11. Ganguly T, Dannoon S, Hopkins MR, Murphy S, Cahaya H, Blecha JE, Jivan S, Drake CR, Barinka C, Jones EF, VanBrocklin HF, Berkman CE. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Nucl Med Biol. 2015 Oct; 42(10):780-7.
    View on PubMed
  12. Hope TA, Aggarwal R, Simko JP, VanBrocklin HF, Ryan CJ. Somatostatin imaging of neuroendocrine-differentiated prostate cancer. Clin Nucl Med. 2015 Jun; 40(6):540-1.
    View on PubMed
  13. Ley CR, Beattie NR, Dannoon S, Regan M, VanBrocklin H, Berkman CE. Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen. Bioorg Med Chem Lett. 2015 Jun 15; 25(12):2536-9.
    View on PubMed
  14. LeBeau AM, Sevillano N, Markham K, Winter MB, Murphy ST, Hostetter DR, West J, Lowman H, Craik CS, VanBrocklin HF. Imaging active urokinase plasminogen activator in prostate cancer. Cancer Res. 2015 Apr 1; 75(7):1225-35.
    View on PubMed
  15. Carroll V, Michel BW, Blecha J, VanBrocklin H, Keshari K, Wilson D, Chang CJ. A boronate-caged [¹8F]FLT probe for hydrogen peroxide detection using positron emission tomography. J Am Chem Soc. 2014 Oct 22; 136(42):14742-5.
    View on PubMed
  16. Schwarz SW, Dick D, VanBrocklin HF, Hoffman JM. Regulatory Requirements for PET Drug Production. J Nucl Med. 2014 Jul; 55(7):1132-7.
    View on PubMed
  17. James SL, Ahmed SK, Murphy S, Braden MR, Belabassi Y, VanBrocklin HF, Thompson CM, Gerdes JM. A novel fluorine-18 ß-fluoroethoxy organophosphate positron emission tomography imaging tracer targeted to central nervous system acetylcholinesterase. ACS Chem Neurosci. 2014 Jul 16; 5(7):519-24.
    View on PubMed
  18. LeBeau AM, Sevillano N, King ML, Duriseti S, Murphy ST, Craik CS, Murphy LL, VanBrocklin HF. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance. Theranostics. 2014; 4(3):267-79.
    View on PubMed
  19. Nordstrom R, Cherry S, Azhdarinia A, Sevick-Muraca E, Vanbrocklin H. Photons across medicine: relating optical and nuclear imaging. Biomed Opt Express. 2013; 4(12):2751-62.
    View on PubMed
  20. Keshari KR, Sai V, Wang ZJ, Vanbrocklin HF, Kurhanewicz J, Wilson DM. Hyperpolarized [1-13C]dehydroascorbate MR spectroscopy in a murine model of prostate cancer: comparison with 18F-FDG PET. J Nucl Med. 2013 Jun; 54(6):922-8.
    View on PubMed

Go to UCSF Profiles, powered by CTSI